日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan

针对既往接受过治疗且伴有腹膜播散的胃癌患者,采用溶剂型或白蛋白结合型紫杉醇联合雷莫芦单抗治疗,并进行预先设定的生物标志物分析(P-SELECT/WJOG10617G):一项在日本开展的随机II期临床试验

Hirata, Kenro; Hamamoto, Yasuo; Shoji, Hirokazu; Hara, Hiroki; Kondoh, Chihiro; Yasui, Hisateru; Kajiwara, Takeshi; Baba, Eishi; Ando, Takayuki; Sugimoto, Naotoshi; Kawakami, Hisato; Katsuya, Hiroo; Nagase, Michitaka; Yamamoto, Yoshiyuki; Yoshimura, Kenichi; Ando, Masahiko; Imamura, Chiyo K; Yamazaki, Kentaro; Hironaka, Shuichi; Muro, Kei

Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701

晚期胃癌伴广泛淋巴结转移患者接受围手术期卡培他滨联合奥沙利铂治疗的II期临床试验的长期生存结果:OGSG 1701

Endo, Shunji; Kimura, Yutaka; Sugimoto, Naotoshi; Kawabata, Ryohei; Takeno, Atsushi; Tamura, Shigeyuki; Matsuyama, Jin; Nakamura, Masato; Takeshita, Hiroki; Imano, Motohiro; Yasuda, Atsushi; Satake, Hironaga; Boku, Shogen; Kotaka, Masahito; Takeoka, Tomohira; Kurokawa, Yukinori; Tsujinaka, Toshimasa; Shimokawa, Toshio; Satoh, Taroh

Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment

高肿瘤突变负荷不可切除胰腺癌患者的遗传和临床特征及帕博利珠单抗治疗的疗效

Kai, Yugo; Ikezawa, Kenji; Kozumi, Kazuhiro; Urabe, Makiko; Takada, Ryoji; Kinomoto, Takumi; Masumoto, Takanori; Kawabata, Masaki; Kishimoto, Hiroki; Hosokawa, Kana; Mukai, Kaori; Nakabori, Tasuku; Yamaguchi, Yuko; Sugimoto, Naotoshi; Ohkawa, Kazuyoshi

Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)

曲妥珠单抗-德鲁替康治疗 HER2 阳性晚期胃癌日本患者的真实世界疗效和安全性(EN-DEAVOR 研究)

Kawakami, Hisato; Nakanishi, Koki; Makiyama, Akitaka; Konishi, Hirotaka; Morita, Satoshi; Narita, Yukiya; Sugimoto, Naotoshi; Minashi, Keiko; Imano, Motohiro; Inamoto, Rin; Kodera, Yasuhiro; Kume, Hiroki; Yamaguchi, Keita; Hashimoto, Wataru; Muro, Kei

ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

ONO-4578联合纳武利尤单抗治疗不可切除的晚期或复发性胃癌或胃食管交界处癌

Kawazoe, Akihito; Yamaguchi, Kensei; Hamaguchi, Tetsuya; Narita, Yukiya; Boku, Shogen; Oshima, Takashi; Hara, Hiroki; Hamamoto, Yasuo; Ishido, Kenji; Esaki, Taito; Hosaka, Hisashi; Yasui, Hirofumi; Koeda, Keisuke; Nishina, Tomohiro; Tsuji, Yasushi; Fukagawa, Takeo; Goto, Masahiro; Oki, Eiji; Sugimoto, Naotoshi; Matsuoka, Hiroshi; Yokoyama, Fumiharu; Yoshida, Tomoko; Yoshida, Kazuo; Oshima, Yoshiaki; Iwasa, Satoru

Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations

伴有少量RAS突变的转移性结直肠癌的临床和预后特征

Kojitani, Yoshiki; Sakai, Daisuke; Ogata, Takatsugu; Amano, Yumi; Mori, Ryota; Kitakaze, Masatoshi; Sueda, Toshinori; Otsuka, Tomoyuki; Nishio, Minako; Ishihara, Mikiya; Kagawa, Yoshinori; Nishimura, Junichi; Sugimoto, Naotoshi; Yagi, Toshinari; Takeda, Masayuki; Yasui, Masayoshi; Kudo, Toshihiro

Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102

卡培他滨联合贝伐单抗治疗老年转移性结直肠癌患者的II期临床试验:OGSG 1102

Yamaguchi, Toshifumi; Yoshida, Motoki; Taira, Koichi; Tokunaga, Shinya; Kato, Takeshi; Nakamura, Masato; Sugimoto, Naotoshi; Fumita, Soichi; Yasui, Masayoshi; Miyake, Yasuhiro; Kawakami, Hisato; Kurokawa, Yukinori; Shimokawa, Toshio; Satoh, Taroh

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

曲妥珠单抗德鲁替康治疗HER2阳性晚期胃癌:随机II期DESTINY-Gastric01试验的探索性生物标志物分析

Shitara, Kohei; Bang, Yung-Jue; Iwasa, Satoru; Sugimoto, Naotoshi; Ryu, Min-Hee; Sakai, Daisuke; Chung, Hyun Cheol; Kawakami, Hisato; Yabusaki, Hiroshi; Sakamoto, Yasuhiro; Nishina, Tomohiro; Inaki, Koichiro; Kuwahara, Yusuke; Wada, Naoya; Suto, Fumitaka; Arita, Takeo; Sugihara, Masahiro; Tsuchihashi, Zenta; Saito, Kaku; Kojima, Akihito; Yamaguchi, Kensei

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

脂质体艾立布林(E7389-LF)联合纳武利尤单抗治疗胃癌队列的II期研究结果

Kawazoe, Akihito; Yamamoto, Noboru; Sugimoto, Naotoshi; Kawakami, Hisato; Oshima, Takashi; Yamaguchi, Kensei; Hino, Kaori; Hirao, Motohiro; Kurokawa, Yukinori; Kawakami, Takeshi; Tsuda, Masahiro; Hara, Hiroki; Kaname, Shota; Matsuoka, Daiko; Otake, Yohei; Yasuda, Keisuke; Takase, Takao; Takashima, Shuya; Semba, Taro; Muro, Kei

Case report: A family of atypical hemolytic uremic syndrome involving a CFH::CFHR1 fusion gene and CFHR3-1-4-2 gene duplication

病例报告:一例涉及CFH::CFHR1融合基因和CFHR3-1-4-2基因重复的非典型溶血性尿毒综合征家族

Tasaki, Yuko; Tsujimoto, Hiroshi; Yokoyama, Tadafumi; Sugimoto, Naotoshi; Kitajima, Shinji; Fujii, Hiroshi; Hidaka, Yoshihiko; Kato, Noritoshi; Maruyama, Shoichi; Inoue, Norimitsu; Wada, Taizo